Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polidocanol 1% vs Triamcinolone Acetonide in Keloids and Hypertrophic Scars
NCT07606391Not yet recruiting
- Sponsor
- Sohag University
- Start
- Aug 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of 10XB101 in keloid and Hypertrophic Scar (HS) (3 arms), sponsored by Sohag University. Primary endpoints: Improvement and flattening of keloids and hypertrophic scars by photographic assessment and Vancouver Scar Scale. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
10XB101
03
Conditions
keloidHypertrophic Scar (HS)
Beyond the preview
Go deeper on NCT07606391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606391.